Evidence

Discover our latest testimonials and publications

Testimonials

Dr. Carlo Brugnara - Director, Hematology Lab

Boston Children's Hospital - Boston, US
OLO’s performance is comparable to analyzers that are 50 times bigger and much more complicated to operate. The ability to take that much analytical power outside of the central lab and bring it to any setting where you can perform a CBC analysis in minutes has huge implications for hospital wards, such as oncology clinics, emergency rooms, neonatal intensive care units, and beyond.

Dr. Steven Melnick - Chief, Department of Pathology

Nicklaus Children's Hospital - Miami, US
To treat children in our urgent care centers, a CBC is essential. OLO represents a major innovation in our laboratories’ CBC analysis: low blood volume (finger-prick) sampling for a five-part differential with flagging. It’s a truly welcome development. At current volumes, we believe OLO could substantially reduce our costs.

Pamala Travis - Technical Specialist for Point of Care

University of Cincinnati Medical Center - Ohio, US
OLO makes near patient testing a reality at UC Health. I am impressed with the 5-part diff accuracy and the 10 minutes turnaround time. All it takes is 2 drops of blood in one cuvette, without any wet consumables. Best of all, no calibration or maintenance. It's truly a game changer.

Helen Light - Research Nurse, Pennine MSK Partnership

Oldham Integrated Care Centre - Manchester, UK
OLO has user friendly prompts for each step of the preparation so it’s impossible to go wrong. It even completes its own QC checks. It can be invaluable to have the patient's FBC within the consultation.

Dr. Ram Doolman - Director, Laboratories Division & Automated Mega-Laboratory

Sheba Tel Hashomer Medical Center - Tel Aviv, ISR
The Sight OLO successfully completed a comprehensive evaluation study at the Sheba Tel Hashomer Medical Center. The evaluation compared OLO’s performances to a state-of-the-art analyzer and experienced microscopists, across a wide clinical range. OLO’s excellent performance exceeded predefined acceptance criteria in all aspects. Following the evaluation, we have started a research collaboration with the aim to explore the diagnostic potential of visual signatures in the blood images among different patient populations, including those with COVID-19.

Regulatory Submissions

FDA 510 (k) Clearance
May, 4th 2019
Meet the team behind Sight